Table 1. Baseline characteristics of treatment-naïve patients diagnosed with cancer (n = 555).
| Treatment-naïve cancer patients (n= 555) | |
|---|---|
| Age, years (IQR) | 62 (52-71) |
| Male gender, n (%) | 227 (41%) |
| BMI kg/m2, (IQR) | 25.0 (22.6–28.4) |
| Comorbidities | |
| Known CAD, n (%) | 28 (5%) |
| Heart Failure, n (%) | 38 (7%) |
| Diabetes mellitus, n (%) | 43 (8%) |
| Arterial Hypertension, n (%) | 250 (45%) |
| CKD, n (%) | 31 (6%) |
| COPD, n (%) | 113 (20%) |
| Cancer disease stage* | |
| Stage 1, n (%) | 96 (17%) |
| Stage 2, n (%) | 50 (9%) |
| Stage 3, n (%) | 108 (19%) |
| Stage 4, n (%) | 183 (33%) |
| Hepatic involvement | |
| Primary hepatic, biliary tract or pancreatic malignoma, n (%) | 27 (5%) |
| Hepatic metastases, n (%) | 51 (10%) |
| Laboratory parameters | |
| GFR, mL/min/1.73 m2 (IQR) | 74.5 (63.7–86.0) |
| BUN, mg/dl (IQR) | 15 (12-19) |
| BChE, kU/l (IQR) | 7.31 (6.10–8.40) |
| AST (GOT), U/l (IQR) | 24 (19–31) |
| ALT (GPT), U/l (IQR) | 22 (16–32) |
| GGT, U/l (IQR) | 32 (21–63) |
| Bilirubin, mg/dl (IQR) | 0.58 (0.44-0.79) |
| Albumin, g/l (IQR) | 43.0 (40.0–45.4) |
| CRP, mg/dl (IQR) | 0 (0-1) |
| SAA, μg/ml (IQR) | 8 (4-26) |
| IL-6, pg/ml (IQR) | 2 (2–3) |
Continuous variables are given as medians and inter-quartile ranges (IQR). Counts are given as numbers and percentages.
IQR – interquartile range; BMI – body mass index, CAD – coronary artery disease; CKD – chronic kidney disease; COPD – chronic obstructive pulmonary disease; GFR – glomerular filtration rate; BUN – blood urea nitrogen; BChE – butyryl-cholinesterase, AST – aspartate transaminase, ALT – alanine transaminase, GGT – gamma glutamyltransferase; CRP - C-reactive protein; SAA - Serum Amyloid A; IL-6 – interleukin 6.
* tumor stage was assessed by the respective treating oncologist and was indicated for all patients excluding those with myeloproliferative neoplasias.